HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection

(2015)   JOURNAL OF HEPATOLOGY

Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy

(2013) Wai-Kay Seto et al.   HEPATOLOGY

Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir

(2012) Stephanos J. Hadziyannis et al.   GASTROENTEROLOGY

Restored Function of HBV-Specific T Cells After Long-term Effective Therapy With Nucleos(t)ide Analogues

(2012) Carolina Boni et al.   GASTROENTEROLOGY

A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance

(2012) Wai-Kay Seto et al.   HEPATOLOGY

HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years

(2012) Massimo Fasano et al.   JOURNAL OF HEPATOLOGY

Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely

(2012) Stéphane Chevaliez et al.   JOURNAL OF HEPATOLOGY

A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection

(2012) Jessica Liu et al.   JOURNAL OF HEPATOLOGY

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

(2012) Patrick Marcellin et al.   LANCET

Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients

(2011) Henry L-Y Chan et al.   ANTIVIRAL THERAPY

Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues

(2011) Jerzy Jaroszewicz et al.   ANTIVIRAL THERAPY

Prevalence of and Risk Factors for Hepatitis B Viremia After Spontaneous Hepatitis B Surface Antigen Seroclearance in Hepatitis B Carriers

(2011) C.-M. Chu et al.   CLINICAL INFECTIOUS DISEASES

Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load

(2011) Tai-Chung Tseng et al.   HEPATOLOGY

Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report

(2011) Henry Lik-Yuen Chan et al.   JOURNAL OF HEPATOLOGY

Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss

(2011) Roeland Zoutendijk et al.   JOURNAL OF INFECTIOUS DISEASES

Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy

(2010) Chau-Ting Yeh   ANTIVIRAL THERAPY

Three-Year Efficacy and Safety of Tenofovir Disoproxil Fumarate Treatment for Chronic Hepatitis B

(2010) E. Jenny Heathcote et al.   GASTROENTEROLOGY

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B

(2010) Ting-Tsung Chang et al.   HEPATOLOGY

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients

(2010) Karsten Wursthorn et al.   HEPATOLOGY

Comparison of the technical and clinical performance of the Elecsys® HBsAg II assay with the Architect®, AxSym®, and Advia® Centaur HBsAg screening assays

(2010) S. Louisirirotchanakul et al.   JOURNAL OF MEDICAL VIROLOGY

Chronic hepatitis B: Update 2009

(2009) Anna S. F. Lok et al.   HEPATOLOGY

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study

(2009) Rami Moucari et al.   JOURNAL OF HEPATOLOGY

Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B*

(2009) R. G. Gish et al.   JOURNAL OF VIRAL HEPATITIS

HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma

(2008) Man–Fung Yuen et al.   GASTROENTEROLOGY

Sustained HBeAg and HBsAg Loss After Long-term Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b

(2008) Erik H.C.J. Buster et al.   GASTROENTEROLOGY

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

(2008) Rami Moucari et al.   HEPATOLOGY

Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma

(2008) H.-I. Yang et al.   JNCI-Journal of the National Cancer Institute